JPH09510722A - Injectable dilithromycin solution - Google Patents
Injectable dilithromycin solutionInfo
- Publication number
- JPH09510722A JPH09510722A JP7524954A JP52495495A JPH09510722A JP H09510722 A JPH09510722 A JP H09510722A JP 7524954 A JP7524954 A JP 7524954A JP 52495495 A JP52495495 A JP 52495495A JP H09510722 A JPH09510722 A JP H09510722A
- Authority
- JP
- Japan
- Prior art keywords
- injectable solution
- injectable
- dilithromycin
- solution according
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
(57)【要約】 本発明は、安定で注射可能なジリスロマイシン溶液に関する。 (57) [Summary] The present invention relates to stable, injectable dilithromycin solutions.
Description
【発明の詳細な説明】 注射可能なジリスロマイシン溶液 本発明は、安定で注射可能なジリスロマイシン(dirithromycin)溶液に関する 。 ジリスロマイシンは、エリスロマイシン系の部分合成抗生物質である。ジリス ロマイシンの調製方法及び医薬組成物としてのジリスロマイシンの使用は、公開 されたドイツ特許出願第P 25 15 075 号に最初に開示されている。ジリスロマイ シンは、溶液中での安定性に問題となる性質を幾つか有しているので、通常は、 固体の経口製剤の形態で投与される。水溶液中で、ジリスロマイシンは、直ちに 分解し、エリスロマイシルアミンを生ずる。従って、注射可能な水溶液は、不安 定であり、これまで知られていない。 本発明の目的は、安定で注射可能なジリスロマイシン溶液を提供することであ る。 親油性の注射可能な溶液は、通常、例えば、イソプロピルミリステート及びエ チルオレエート、並びにトリグリセイド類(トリアセチン)等の液体脂肪酸エス テルを含み、又、必要に応じて、エタノール、プロパンジオール、ベンジルアル コール及びゾルケタール(solketal)等の両親媒性又は親水性の有機溶媒を含む。 親油性媒体又は親油性混合物におけるジリスロマイシンの溶解度は、極めて限 定され、これは治療に有効な活性物質濃度が得られないことを意味する。そのよ うな系では、構造が未だわかっていない物質に、活性物質が分解することもあり 得る。 驚くべきことに、少量の水を加えることによって、親油性(油性)の注射可能 な溶液でのジリスロマイシンの溶解度が増加するだけでなく、ジリスロマイシン の安定性も改善されることが、見出されている。 本発明は、ジリスロマイシンを含む、単相で、親油性(油性)の注射可能な水 溶液であって、特定の量の水を含む水溶液に関する。 水の最大量は、溶液が単相系であることにより条件づけられる。水の添加によ って二相系が形成されると直ぐに、ジリスロマイシンの安定性が劇的に低下する ことが、実験から明らかになっている。水を加えた場合に第二相が形成される条 件は、親油性の注射可能な溶液の組成に従う。長鎖の親水性又は両親媒性成分を 高い割合で含む溶液では、水含量が3%だけでも二相系を形成するが、トリアセ チン/エタノールを含む混合物のような、短鎖の親水性成分を含む混合物は、水 含量が20%であっても単相系を形成する。 本発明によれば、最大量の水を含む単相混合溶媒が好ましく、それは、二相混 合溶媒へ変わる臨界のものである。加えることができる水の最大量は、混合溶媒 中の親水性又は両親媒性溶媒(好ましくはエタノール)の量に従う。長鎖脂肪酸 エステルを使用する場合には、水含量は、エタノール含量に基づいて、最大で約 10〜12重量%であってもよい。エタノールの割合が多くなる程、二相系へ変わる 臨界に達するまでに、加えることができる水の最大量も多くなる。エタノール等 の親水性溶媒の割合は、次の二つの要因により制限される:一方は、純粋なエタ ノール/水系中で、ジリスロマイシンが不安定なことであり、他方は、エタノー ルを高い割合で含む注射可能な溶液の注射は非常に痛いということである。許容 できる上限は、エタノールの割合が約50重量%であり、30〜40重量%の範囲が好 ましく、32〜37重量%の範囲が特に好ましい。親水性溶媒(特にエタノール)の 下限は、個々の場合で相当に変わり得るものであり、活性物質を含む注射可能な 溶液の好適な実施態様では、ジリスロマイシン濃度が少なくとも20g/100 mlで あるべきとの必要性から、該下限が条件づけられる。 さらに低い濃度が可能であるが、その場合には、治療に有効な投与量を投与す るために、さらに多くの量を注射する必要がある。これらの限界条件から、例え ば、イソプロピルミリステートエタノール及び水の比が80:20:2の混合溶媒で あって、100 ml中にジリスロマイシン19gを溶かし得る混合溶媒が導かれる。特 に好適な実施態様は、上記の混合溶媒の比が65:35:4であって、100 ml中にジ リスロマイシン32gを溶解し得るものである。 例えば、油性成分としてトリアセチンを含む混合溶媒は、低い含量の親水性溶 媒(例えば、エタノール)と共に、さらに高い割合の水を含むことができる。こ の関係は実施例中の表に見ることができる。 油性混合溶媒中の油及び脂肪酸エステルの例としては、中鎖トリグリセリド ルパルミテート、イソプロピルミリステート、オレイルオレエート(セチオール チルオレエート及びトリアセチンが好ましい。 好適な親水性溶媒は、プロパンジオール、ベンジルアルコール、ポリエチレン グリコール及びゾルケタールである。エタノールが特に好ましい。 次の例は、挙げられた例に発明を限定することなく、本発明を説明するもので ある。 本発明のジリスロマイシン溶液は安定であり、標準的な貯蔵条件で、少なくと も6〜12ヶ月間の長期間を過ぎても、又は、たとえ数年間までであっても、使用 することができる。 ジリスロマイシンの溶解度における水の影響 イソプロピルミリステート/無水エタノール/プロパンジオールを含む系(重 量部で示す): エチルオレエート/ゾルケタールを含む系: イソプロピルミリステート/ベンジルアルコールを含む系: トリアセチン/エタノールを含む系: イソプロピルミリステート/無水エタノールを含む系: ジリスロマイシンの安定度における水の影響 イソプロピルミリステート/エタノールを含む系: イソプロピルミリステート/エタノールを含む系: DETAILED DESCRIPTION OF THE INVENTION Injectable Dilithromycin Solution The present invention relates to a stable and injectable diithromycin solution. Dilithromycin is a partially synthetic antibiotic of the erythromycin system. The method of preparation of dilithromycin and the use of dilithromycin as a pharmaceutical composition were first disclosed in published German patent application P 25 15 075. Dilithromycin is normally administered in the form of a solid oral formulation, since it has some properties that make stability in solution problematic. In aqueous solution, dilithromycin immediately decomposes to give erythromycylamine. Thus, injectable aqueous solutions are unstable and hitherto unknown. It is an object of the invention to provide a stable and injectable dilithromycin solution. Lipophilic injectable solutions usually contain, for example, isopropyl myristate and ethyl oleate, and liquid fatty acid esters such as triglycides (triacetin), and, if necessary, ethanol, propanediol, benzyl alcohol and Includes amphipathic or hydrophilic organic solvents such as solketal. The solubility of dilithromycin in lipophilic vehicles or lipophilic mixtures is very limited, which means that no therapeutically effective concentration of active substance is obtained. In such a system, it is possible for the active substance to decompose into substances whose structure is not yet known. Surprisingly, the addition of a small amount of water not only increases the solubility of dilithromycin in lipophilic (oily) injectable solutions, but also improves the stability of dilithromycin. Have been found. The present invention relates to a single-phase, lipophilic (oleophilic) injectable aqueous solution containing dilithromycin, containing a specified amount of water. The maximum amount of water is conditioned by the solution being a single phase system. Experiments have shown that the stability of dilithromycin decreases dramatically as soon as the biphasic system is formed by the addition of water. The conditions under which the second phase is formed when water is added depend on the composition of the lipophilic injectable solution. A solution containing a high proportion of long-chain hydrophilic or amphipathic constituents forms a biphasic system even with a water content of only 3%, but a short-chain hydrophilic constituent such as a mixture containing triacetin / ethanol is included. The containing mixture forms a single-phase system even with a water content of 20%. According to the invention, a single-phase mixed solvent containing the maximum amount of water is preferred, which is the critical one to convert to a two-phase mixed solvent. The maximum amount of water that can be added depends on the amount of hydrophilic or amphipathic solvent (preferably ethanol) in the mixed solvent. If long chain fatty acid esters are used, the water content may be up to about 10-12% by weight, based on the ethanol content. The higher the proportion of ethanol, the higher the maximum amount of water that can be added before reaching the criticality of a two-phase system. The proportion of hydrophilic solvents such as ethanol is limited by two factors: one is the instability of dilithromycin in the pure ethanol / water system, the other is the high proportion of ethanol. The injection of the injectable solution containing is very painful. An acceptable upper limit is about 50% by weight ethanol, preferably 30-40% by weight, particularly preferably 32-37% by weight. The lower limit of the hydrophilic solvent (especially ethanol) can vary considerably in individual cases, and in a preferred embodiment of the injectable solution containing the active substance the concentration of dilithromycin is at least 20 g / 100 ml. The lower bound is conditioned on the need for power. Lower concentrations are possible, in which case higher doses will need to be injected in order to administer a therapeutically effective dose. From these limiting conditions, for example, a mixed solvent having a ratio of isopropyl myristate ethanol and water of 80: 20: 2 and capable of dissolving 19 g of dilithromycin in 100 ml is derived. A particularly preferred embodiment is the above mixed solvent ratio of 65: 35: 4, which is capable of dissolving 32 g of dilithromycin in 100 ml. For example, a mixed solvent containing triacetin as an oily component may contain a higher proportion of water with a lower content of hydrophilic solvent (eg ethanol). This relationship can be seen in the table in the examples. Examples of oils and fatty acid esters in oily mixed solvents include medium chain triglycerides. Lepalmitate, isopropyl myristate, oleyl oleate (cethiol Cyloleate and triacetin are preferred. Suitable hydrophilic solvents are propanediol, benzyl alcohol, polyethylene glycol and solketal. Ethanol is especially preferred. The following examples illustrate the invention without limiting it to the examples given. The dilithromycin solutions of the present invention are stable and can be used under standard storage conditions for extended periods of at least 6-12 months, or even up to several years. Effect of Water on Solubility of Dilithromycin System containing isopropyl myristate / anhydrous ethanol / propanediol (parts by weight): Systems containing ethyl oleate / solketal: Systems containing isopropyl myristate / benzyl alcohol: Systems containing triacetin / ethanol: Systems containing isopropyl myristate / anhydrous ethanol: Effect of water on the stability of dilithromycin Isopropyl myristate / ethanol containing system: Systems containing isopropyl myristate / ethanol:
Claims (1)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4410637.8 | 1994-03-26 | ||
DE4410637A DE4410637C1 (en) | 1994-03-26 | 1994-03-26 | Injectable solutions of dirithromycin |
PCT/EP1995/001096 WO1995026191A1 (en) | 1994-03-26 | 1995-03-23 | Injectable solutions of dirithromycin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09510722A true JPH09510722A (en) | 1997-10-28 |
Family
ID=6514000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7524954A Pending JPH09510722A (en) | 1994-03-26 | 1995-03-23 | Injectable dilithromycin solution |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0754047A1 (en) |
JP (1) | JPH09510722A (en) |
AU (1) | AU2214195A (en) |
CO (1) | CO4370014A1 (en) |
DE (1) | DE4410637C1 (en) |
WO (1) | WO1995026191A1 (en) |
ZA (1) | ZA952405B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013537222A (en) * | 2010-09-16 | 2013-09-30 | エルジー ライフ サイエンス リミテッド | Non-aqueous oily injectable preparation showing preservative efficacy |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19518917A1 (en) * | 1995-05-23 | 1996-11-28 | Boehringer Ingelheim Vetmed | Stable, concentrated, locally tolerated erythromycylamine solutions |
DE19701949A1 (en) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermal therapeutic system |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT342770B (en) * | 1975-04-07 | 1978-04-25 | Thomae Gmbh Dr K | PROCESS FOR PRODUCING NEW ERYTHROMYCINE DERIVATIVES |
US4918108A (en) * | 1982-03-16 | 1990-04-17 | Boehringer Ingelheim Vetmedica Gmbh | Method of improving the absorption of injected antibacterial substances |
DE3209429A1 (en) * | 1982-03-16 | 1983-10-06 | Boehringer Ingelheim Vetmed | AGENT FOR IMPROVING THE RESORPTION OF INJECTED ANTIBACTERIAL EFFECTIVE SUBSTANCES AND COMBINATIONS CONTAINING A BENZYAMINE DERIVATIVE |
NZ233827A (en) * | 1989-05-26 | 1991-06-25 | Abbott Lab | Pharmaceutical composition comprising clarithromycin, triglyceride oil and stabilising agent |
-
1994
- 1994-03-26 DE DE4410637A patent/DE4410637C1/en not_active Expired - Fee Related
-
1995
- 1995-03-23 EP EP95915148A patent/EP0754047A1/en not_active Withdrawn
- 1995-03-23 AU AU22141/95A patent/AU2214195A/en not_active Abandoned
- 1995-03-23 JP JP7524954A patent/JPH09510722A/en active Pending
- 1995-03-23 CO CO95011794A patent/CO4370014A1/en unknown
- 1995-03-23 WO PCT/EP1995/001096 patent/WO1995026191A1/en not_active Application Discontinuation
- 1995-03-24 ZA ZA952405A patent/ZA952405B/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013537222A (en) * | 2010-09-16 | 2013-09-30 | エルジー ライフ サイエンス リミテッド | Non-aqueous oily injectable preparation showing preservative efficacy |
Also Published As
Publication number | Publication date |
---|---|
WO1995026191A1 (en) | 1995-10-05 |
CO4370014A1 (en) | 1996-10-07 |
DE4410637C1 (en) | 1995-09-21 |
AU2214195A (en) | 1995-10-17 |
ZA952405B (en) | 1995-09-26 |
EP0754047A1 (en) | 1997-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5589455A (en) | Cyclosporin-containing soft capsule compositions | |
US6495160B2 (en) | Biphasic multicomponent pharmaceutical dosage forms containing substances able to modify the partitioning of drugs | |
JP3391961B2 (en) | Cyclosporin-containing soft capsule composition | |
US7182956B2 (en) | Stable topical drug delivery compositions | |
EP1578325B1 (en) | Stable topical drug delivery compositions | |
US20030211123A1 (en) | Vehicles for delivery of biologically active substances | |
KR890700036A (en) | Nasal preparations and preparation methods thereof | |
JP2963537B2 (en) | Injectable composition of clarithromycin | |
KR101590072B1 (en) | Composition for self-emulsifying drug delivery system comprising dutasteride | |
US5747069A (en) | Percutaneously absorbable preparation | |
CN101909664A (en) | Imiquimod formulation | |
EP1320385A1 (en) | Combination compositions | |
JP2004051487A (en) | Percutaneous absorption preparation | |
JP2003503339A (en) | Self-emulsifying system containing anticancer drug | |
CZ83598A3 (en) | Preparation containing cyclosporin and process for preparing thereof | |
WO1997021440A1 (en) | A solution for oral administration containing ici 182,780 | |
JPH09510722A (en) | Injectable dilithromycin solution | |
JPH0413624A (en) | Pyroxycam-containing pharmaceutical composition for topical application | |
AU7155891A (en) | Pharmaceutical formulation | |
JP2973077B2 (en) | Vitamin E preparation composition | |
AU2004246961A1 (en) | Transnasal microemulsions containing diazepam | |
JPH0371409B2 (en) | ||
WO1997004795A2 (en) | Pharmaceutical compositions containing cyclosporin or other peptide substances | |
JP3280712B2 (en) | External preparation for skin | |
GB1593354A (en) | Liquid pharmaceutical formulations |